Does Lowering Eye Pressure Affect the Results Obtained From Objective Visual Field Testing?
A study to determine whether a patient's range of vision test results improve after their eye pressure is lowered by 30% or more by testing on a new machine called the Accumap and how to learn how much the Accumap's results change from one test to another within the same person.
The investigators believe that Multifocal VEP readings (Accumap)(and therefore visual function and ganglion cell function) improve after acutely lowering intraocular pressure.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Effect of Acutely Lowering Intraocular Pressure on Multifocal Visual Evoked Potential Testing|
- lowering of intraocular pressure will cause an acute improvement in MfVEP (multifocal visually evoked potential) amplitude readings [ Time Frame: 1 day ] [ Designated as safety issue: No ]
|Study Start Date:||October 2004|
|Study Completion Date:||January 2007|
|Primary Completion Date:||January 2007 (Final data collection date for primary outcome measure)|
Patients that have medical intervention in an attempt to lower intraocular pressure (oral or topical)
Patients who have received no intervention
Accumap testing will be performed before and two to three hours after treatment is initiated to lower IOP. In eye that have bilateral treatment, one eye will be assigned randomly to the study. The mean multifocal objective perimetry amplitude will be compared before and after IOP reduction. Also, the mean amplitudes of five circumferential zones will be compared before and after IOP lowering. Visual field testing and HRT testing will be performed before and after treatment as well if possible. Paired t-tests will be performed no pre-and post-treatment mean MOP amplitude values and circumferential zones to determine statistical significance. A second group of patients whose pressures will not be lowered will also be tested with Accumap at baseline and two hours afterwards, in order to examine reproducibility of mean MOP amplitude and mean circumferential amplitude. HVF and HRT testing will also be obtained on thes patients when possible.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00799994
|United States, Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19107|
|Principal Investigator:||L. Jay Katz, MD||Wills Eye Institute|